establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.

Summary

The measure creates a program within New Hampshire’s health department that lets licensed providers produce and administer psilocybin to patients with qualifying conditions such as treatment‑resistant depression, PTSD, or substance‑use disorders. It also establishes a medical psilocybin advisory board to monitor the program and evaluate safety and effectiveness. Providers who follow the program would be exempt from criminal penalties for handling therapeutic amounts of the drug.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share